Russell Investments Group Ltd. Purchases 236,255 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Russell Investments Group Ltd. boosted its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 62.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 613,032 shares of the biotechnology company's stock after purchasing an additional 236,255 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.27% of ADMA Biologics worth $2,771,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. lifted its stake in ADMA Biologics by 31.3% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 15,000 shares of the biotechnology company's stock worth $54,000 after purchasing an additional 3,572 shares in the last quarter. Sawgrass Asset Management LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at about $55,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at about $58,000. Commonwealth Equity Services LLC raised its position in shares of ADMA Biologics by 61.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,360 shares of the biotechnology company's stock valued at $59,000 after buying an additional 6,250 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at about $65,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms sold 49,887 shares of the stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $6.01, for a total value of $299,820.87. Following the completion of the sale, the director now owns 2,527,500 shares in the company, valued at approximately $15,190,275. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have sold 639,895 shares of company stock worth $3,927,169. 3.70% of the stock is owned by insiders.

ADMA Biologics Stock Performance

Shares of NASDAQ:ADMA traded up $0.37 during midday trading on Tuesday, reaching $9.16. The company's stock had a trading volume of 3,767,616 shares, compared to its average volume of 2,728,425. The firm has a market capitalization of $2.09 billion, a PE ratio of -458.00 and a beta of 0.43. ADMA Biologics, Inc. has a twelve month low of $3.06 and a twelve month high of $9.17. The stock has a fifty day moving average of $6.52 and a 200 day moving average of $5.23. The company has a quick ratio of 1.86, a current ratio of 5.21 and a debt-to-equity ratio of 0.91.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.05 by $0.03. The company had revenue of $81.90 million for the quarter, compared to analyst estimates of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The firm's revenue was up 43.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.03) earnings per share. On average, equities analysts expect that ADMA Biologics, Inc. will post 0.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on ADMA. Cantor Fitzgerald upped their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company an "overweight" rating in a report on Friday. Raymond James upped their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a "strong-buy" rating in a report on Friday. HC Wainwright upped their price target on shares of ADMA Biologics from $7.50 to $10.00 and gave the company a "buy" rating in a report on Friday. Finally, Mizuho upped their price target on shares of ADMA Biologics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $10.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.